Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
MTAPESTRY 101
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
- NCT05094336 ↗
- Active, not recruiting
- Amgen
- Focused
We haven't built an HCP commentary report on MTAPESTRY 101 (anvumetostat (AMG 193); anvumetostat (AMG 193) plus docetaxel in advanced MTAP-null solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MTAPESTRY 101 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Advanced MTAP-null Solid Tumors
- Interventions
- Anvumetostat; Docetaxel; Comparator Anvumetostat Test Tablet
- Arms
- Part 1a, Phase 1: Anvumetostat Monotherapy Dose Exploration · Experimental
- Part 1c, Phase 1: Anvumetostat Monotherapy Dose Expansion · Experimental
- Part 2a, Phase 1: Anvumetostat Dose Exploration + Docetaxel · Experimental
- Part 2b, Phase 1: Anvumetostat + Docetaxel Dose Expansion · Experimental
- Part 3: Anvumetostat Phase 2 · Experimental
- Part 1e, Phase 1: Anvumetostat Monotherapy Dose Expansion · Experimental
- Part 1f, Phase 1: Anvumetostat Monotherapy Dose Expansion · Experimental
- Part 1g, Phase 1: Anvumetostat Monotherapy Dose Expansion · Experimental
- Part 1h, Phase 1: Anvumetostat Monotherapy Dose Expansion · Experimental
- Part 1i, Phase 1: Anvumetostat Dose Optimization · Experimental
- Part 1j, Phase 1: Anvumetostat DSPS Substudy (US Sites Only) · Experimental
- Part 1k, Phase 1: Anvumetostat Food Effect Substudy (US Sites Only) · Experimental
- Part 1l, Phase 1: Anvumetostat Monotherapy Dose Expansion · Experimental
- Part 1m, Phase 1: Anvumetostat Monotherapy Dose Expansion · Experimental
- Enrollment
- 329
- Primary outcomes
- Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
- Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
- Part 3: Objective Response Rate (ORR)
- Sponsor
- Amgen
- Start
- Feb 1, 2022
- Primary completion
- Nov 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05094336 · updated May 28, 2026